In addition, SEC6‐positive expression consistently predicted high‐risk patients showing characteristics of stem‐cell signature, MSI, dMMR, and CIMP+ status as well as BRAF mutations, which are commonly associated with worse prognosis in CRC [31, 32]. The gene discussed is BRAF; the disease is colorectal carcinoma.